We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Exelixis Inc (EXEL) Com Stk Usd0.001

Sell:$19.22 Buy:$19.23 Change: $0.27 (1.38%)
NASDAQ:0.58%
Market closed |  Prices as at close on 11 August 2022 | Switch to live prices |
Sell:$19.22
Buy:$19.23
Change: $0.27 (1.38%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 11 August 2022 | Switch to live prices |
Sell:$19.22
Buy:$19.23
Change: $0.27 (1.38%)
Market closed |  Prices as at close on 11 August 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Contact details

Address:
1851 Harbor Bay Parkway
ALAMEDA
94502
United States
Telephone:
+1 (650) 8377000
Website:
https://www.exelixis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EXEL
ISIN:
US30161Q1040
Market cap:
$6.75 billion
Shares in issue:
320.74 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Morrissey
    President, Chief Executive Officer, Director
  • Christopher Senner
    Chief Financial Officer, Executive Vice President
  • Peter Lamb
    Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey Hessekiel
    Executive Vice President, General Counsel, Secretary
  • Vicki Goodman
    Executive Vice President - Product Development and Medical Affairs, Chief Medical Officer
  • Patrick Haley
    Executive Vice President - Commercial

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.